News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
110,426 Results
Type
Article (7576)
Company Profile (78)
Press Release (102772)
Multimedia
Podcasts (10)
Webinars (2)
Section
Business (38811)
Career Advice (211)
Deals (17359)
Drug Delivery (20)
Drug Development (9925)
Employer Resources (20)
FDA (1885)
Job Trends (2895)
News (66659)
Policy (3914)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (3)
2024 Biotech Bay Standard (4)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Genetown Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (280)
Adcomms (1)
Allergies (9)
Alliances (8498)
ALS (5)
Alzheimer's disease (90)
Antibody-drug conjugate (ADC) (44)
Approvals (1897)
Artificial intelligence (32)
Autoimmune disease (5)
Automation (4)
Bankruptcy (82)
Best Places to Work (2093)
BIOSECURE Act (2)
Biosimilars (18)
Biotechnology (56)
Bladder cancer (8)
Brain cancer (9)
Breast cancer (38)
Cancer (312)
Cardiovascular disease (19)
Career advice (187)
Career pathing (7)
CAR-T (23)
Cell therapy (73)
Cervical cancer (5)
Clinical research (7994)
Collaboration (180)
Compensation (63)
Complete response letters (1)
COVID-19 (379)
CRISPR (7)
C-suite (56)
Cystic fibrosis (4)
Data (274)
Denatured (3)
Depression (7)
Diabetes (25)
Diagnostics (1253)
Digital health (4)
Diversity (1)
Diversity, equity & inclusion (2)
Drug discovery (24)
Drug pricing (8)
Drug shortages (4)
Duchenne muscular dystrophy (16)
Earnings (16046)
Editorial (6)
Employer branding (3)
Employer resources (17)
Events (11615)
Executive appointments (192)
FDA (2034)
Featured Employer (6)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (150)
Gene editing (17)
Generative AI (1)
Gene therapy (49)
GLP-1 (190)
Government (400)
Guidances (11)
Healthcare (2617)
Huntington's disease (3)
IgA nephropathy (9)
Immunology and inflammation (29)
Indications (3)
Infectious disease (399)
Inflammatory bowel disease (33)
Inflation Reduction Act (6)
Influenza (10)
Intellectual property (30)
Interviews (18)
IPO (3367)
IRA (8)
Job creations (863)
Job search strategy (171)
Kidney cancer (4)
Labor market (6)
Layoffs (127)
Leadership (3)
Legal (1128)
Liver cancer (13)
Lung cancer (55)
Lymphoma (16)
Management (7)
Manufacturing (73)
MASH (7)
Medical device (2009)
Medtech (2009)
Mergers & acquisitions (14361)
Metabolic disorders (97)
Multiple sclerosis (20)
NASH (1)
Neurodegenerative disease (16)
Neuropsychiatric disorders (8)
Neuroscience (185)
NextGen: Class of 2025 (1114)
Non-profit (288)
Northern California (586)
Now hiring (6)
Obesity (63)
Opinion (53)
Ovarian cancer (12)
Pain (15)
Pancreatic cancer (6)
Parkinson's disease (15)
Partnered (6)
Patents (46)
Patient recruitment (12)
Peanut (4)
People (12314)
Pharmaceutical (16)
Pharmacy benefit managers (1)
Phase I (2588)
Phase II (3678)
Phase III (2877)
Pipeline (274)
Policy (17)
Postmarket research (160)
Preclinical (1100)
Press Release (3)
Prostate cancer (12)
Psychedelics (5)
Radiopharmaceuticals (56)
Rare diseases (55)
Real estate (1093)
Recruiting (9)
Regulatory (2683)
Reports (11)
Research institute (277)
Resumes & cover letters (29)
Rett syndrome (2)
RNA editing (1)
RSV (1)
Schizophrenia (25)
Series A (41)
Series B (7)
Service/supplier (3)
Sickle cell disease (8)
Southern California (548)
Special edition (3)
Spinal muscular atrophy (14)
Sponsored (5)
Startups (1007)
State (1)
Stomach cancer (1)
Supply chain (13)
Tariffs (2)
The Weekly (7)
United States (3944)
Vaccines (82)
Venture capitalists (13)
Weight loss (48)
Women's health (2)
Worklife (1)
Date
Today (33)
Last 7 days (154)
Last 30 days (487)
Last 365 days (5908)
2025 (1928)
2024 (6349)
2023 (7265)
2022 (9530)
2021 (10436)
2020 (9390)
2019 (7006)
2018 (5721)
2017 (5781)
2016 (5174)
2015 (6179)
2014 (4282)
2013 (3225)
2012 (3644)
2011 (3789)
2010 (3456)
Location
Africa (128)
Alabama (4)
Arizona (36)
Asia (6992)
Australia (893)
California (1383)
Canada (403)
China (92)
Colorado (40)
Connecticut (42)
Delaware (19)
Europe (14912)
Florida (171)
Georgia (24)
Idaho (8)
Illinois (70)
India (3)
Indiana (76)
Iowa (1)
Japan (37)
Kansas (15)
Kentucky (3)
Louisiana (4)
Maine (4)
Maryland (85)
Massachusetts (733)
Michigan (32)
Minnesota (45)
Missouri (6)
Montana (1)
Nebraska (2)
Nevada (7)
New Hampshire (10)
New Jersey (273)
New Mexico (1)
New York (186)
North Carolina (206)
North Dakota (2)
Northern California (586)
Ohio (54)
Oklahoma (2)
Oregon (8)
Pennsylvania (179)
Rhode Island (7)
South America (207)
South Carolina (4)
Southern California (548)
Tennessee (48)
Texas (115)
Utah (20)
Virginia (16)
Washington D.C. (3)
Washington State (113)
West Virginia (2)
Wisconsin (13)
110,426 Results for "sofie sofie biosciences acquired zevacor".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Life Molecular Imaging and SOFIE announce Neuraceq® availability in Cleveland
Life Molecular Imaging and SOFIE Biosciences, a national US manufacturer and developer of PET radiopharmaceuticals, announce that the companies have expanded their strategic partnership and licensing agreement to provide and distribute Neuraceq® out of SOFIE’s radiopharmaceutical manufacturing site located in Cleveland, Ohio.
April 5, 2024
·
5 min read
Press Releases
Life Molecular Imaging and SOFIE announce Neuraceq® availability in Somerset, NJ
January 7, 2025
·
6 min read
Business
RLS and Sofie Enter Strategic Partnership for Distribution of Nuclear Medicine Doses for Patients
RLS, Inc., the third-largest nuclear medicine pharmacy network in the US, and SOFIE Biosciences, a national US manufacturer and developer of PET radiopharmaceuticals, entered into a strategic partnership for RLS to distribute SOFIE nuclear medicine doses for patients.
June 21, 2023
·
2 min read
Drug Development
First Patient Imaged in SOFIE’s 18F-FAPI Phase 2 trial
SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged the first patient with [18F]FAPI-74 in its US Clinical Trial of flourine-18 labeled Fibroblast Activation Protein Inhibitor (FAPI).
May 12, 2023
·
2 min read
Biotech Beach
NEURELIS TO PARTICIPATE IN 11th ANNUAL SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT
Neurelis Inc., is proud to take part in the 11th Annual Sofie’s Journey Epilepsy Awareness Day and Education Expo at Disneyland Resort (EADDL), the largest, worldwide epilepsy community gathering of the year.
October 30, 2023
·
9 min read
Drug Development
First Patient Imaged in SOFIE’s FAPI Phase II trial
SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged the first patient with [ 68 Ga]FAPI-46 at NYU Langone in its US Clinical Trial of Fibroblast Activation Protein Inhibitor (FAPI).
October 13, 2022
·
3 min read
Drug Development
SOFIE granted IND for 18F-FAPI in Phase 2 study
SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has received Investigational New Drug (IND) clearance to proceed with clinical study of [18F]FAPI-74, its lead fluorine-18 labelled Fibroblast Activation Protein Inhibitor (FAPI) product.
November 29, 2022
·
2 min read
Policy
IND granted for FAP targeting therapeutic in SOFIE partnership
SOFIE Biosciences, an established US manufacturer and developer of radiopharmaceuticals, will be supporting, through companion diagnostic [68Ga]FAPI-46 PET, Yantai LNC Biotechnology’s recently FDA accepted clinical study.
January 17, 2023
·
3 min read
Press Releases
Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio
February 28, 2025
·
11 min read
Press Releases
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
April 3, 2025
·
4 min read
1 of 11,043
Next
